Course Access
- This topic is empty.
-
Posts
-
Hello All,
Looking for your clinical opinion on the current Position Statement of the Gastroenterological Society of Australia (GESA) on the use of simethicone as a de-foaming agent during gastrointestinal endoscopy. GESA conclude that,
given the evidence of improved quality of endoscopic imaging and polyp detection, without evidence of clinical adverse events over decades of use , we believe that continued use of simethicone is appropriate and it can be administered through any endoscope channel. We also emphasise the strict adherence to instrument reprocessing protocols is essential.
Has any endoscope units ceased or commenced the use of simethicone? If you use simethicone, do you do any increased surveillance / testing?
We are trying to canvas general opinion to make a sound clinical judgement on the use of simethicone in our endoscopy unit given the risk of simethicone residue in endoscopes channels despite high level disinfection , which can promote biofilm and thereby increase the risk of transmission of micro-organism, and the lack of evidence to support the position statement and the recommendation to conduct further research.
Regards
Robyn FreemanClinical Nurse Consultant Infection Prevention and Control | Kyneton District Health
7-25 Caroline Chisholm Drive, PO Box 34, Kyneton VIC 3444Please Note: I work Wednesday &Thursday
t. (03) 5422 9985 | f. (03) 5422 9918
rfreeman@kynetonhealth.org.au | http://www.kynetonhealth.org.auWe care that every person has a positive experience every time.
KDH acknowledges the Dja Dja Wurrung / Jaara and the Tuangurung Aboriginal people as the shared traditional custodians of the land on which we operate. We commit to working respectfully to honour their ongoing cultural and spiritual connections to this country.
Please consider the environment before printing this e-mail
THIS E-MAIL IS CONFIDENTIAL. If you have received this e-mail in error, please notify us by return e-mail and delete the document. If you are not the intended recipient you are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Kyneton District Health is not liable for the proper and complete transmission of the information contained in this communication or for any delay in its receipt.
MESSAGES POSTED TO THIS LIST ARE SOLELY THE OPINION OF THE AUTHOR, AND DO NOT REPRESENT THE OPINION OF ACIPC.The use of trade/product/commercial brand names through the list is discouraged by ACIPC. If you wish to discuss specific reference to products or services by brand or commercial names, please do this outside the list.
Archive of all messages are available at http://aicalist.org.au/archives – registration and login required.
Replies to this message will be directed back to the list. To create a new message send an email to acipclist@acipc.org.au
To send a message to the list administrator send an email to admin@acipc.org.au
You can unsubscribe manually from this list by sending ‘signoff acipclist’ (without the quotes) to listserv@aicalist.org.au
Hi Robyn
An upfront disclaimer: I work directly at my facility with Dr Ben Devereaux, lead author of this statement.
We have continued use of very low dose simethicone in our endoscopy unit for many years. We recognise that simethicone may enhance biofilm build up, like many fluids that can travel though an endoscope channel. So we have good chemical and physical processes in place to try and minimize biofilm build up and help remove biofilm, including use of cleaning chemicals that enhance biofilm removal, and prompt bedside flushing of all channels post procedure.
I support the clinical use of simethicone in my endoscopy unit as we have very good cleaning, reprocessing and storage processes here, and our biological testing regimes follow all current GENCA and AS4187 guidelines.
I would recommend that any unit using or wishing to use simethicone should review their own endoscope cleaning and reprocessing processes, and their biological testing regimes.
Cheers
MichaelMichael Wishart | Infection Control Coordinator, CICP-E
St Vincents Private Hospital Northside | 627 Rode Road CHERMSIDE QLD 4032
T +61 7 3326 3068 | F +61 7 3607 2226
E michael.wishart@svha.org.au |
W https://www.svphn.org.au—–Original Message—–
From: ACIPC Infexion Connexion On Behalf Of Robyn Freeman
Sent: Wednesday, 24 July 2019 11:05 AM
To: ACIPCLIST@ACIPC.ORG.AU
Subject: [ACIPC_Infexion_Connexion] Simethicone Use During Gastrointestinal Endoscopy: Position Statement of the Gastroenterological Society of AustraliaHello All,
Looking for your clinical opinion on the current Position Statement of the Gastroenterological Society of Australia (GESA) on the use of simethicone as a de-foaming agent during gastrointestinal endoscopy. GESA conclude that,
given the evidence of improved quality of endoscopic imaging and polyp detection, without evidence of clinical adverse events over decades of use , we believe that continued use of simethicone is appropriate and it can be administered through any endoscope channel. We also emphasise the strict adherence to instrument reprocessing protocols is essential.
Has any endoscope units ceased or commenced the use of simethicone? If you use simethicone, do you do any increased surveillance / testing?
We are trying to canvas general opinion to make a sound clinical judgement on the use of simethicone in our endoscopy unit given the risk of simethicone residue in endoscopes channels despite high level disinfection , which can promote biofilm and thereby increase the risk of transmission of micro-organism, and the lack of evidence to support the position statement and the recommendation to conduct further research.
Regards
Robyn FreemanClinical Nurse Consultant Infection Prevention and Control | Kyneton District Health
7-25 Caroline Chisholm Drive, PO Box 34, Kyneton VIC 3444Please Note: I work Wednesday &Thursday
t. (03) 5422 9985 | f. (03) 5422 9918
rfreeman@kynetonhealth.org.au | https://clicktime.symantec.com/3XUksoCrHrx1Uf3jRKAYFck7Vc?u=www.kynetonhealth.org.auWe care that every person has a positive experience every time.
KDH acknowledges the Dja Dja Wurrung / Jaara and the Tuangurung Aboriginal people as the shared traditional custodians of the land on which we operate. We commit to working respectfully to honour their ongoing cultural and spiritual connections to this country.
Please consider the environment before printing this e-mail THIS E-MAIL IS CONFIDENTIAL. If you have received this e-mail in error, please notify us by return e-mail and delete the document. If you are not the intended recipient you are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Kyneton District Health is not liable for the proper and complete transmission of the information contained in this communication or for any delay in its receipt.
MESSAGES POSTED TO THIS LIST ARE SOLELY THE OPINION OF THE AUTHOR, AND DO NOT REPRESENT THE OPINION OF ACIPC.The use of trade/product/commercial brand names through the list is discouraged by ACIPC. If you wish to discuss specific reference to products or services by brand or commercial names, please do this outside the list.
Archive of all messages are available at https://clicktime.symantec.com/3VmzRj1pZFCZrx9gmXadsGM7Vc?u=http%3A%2F%2Faicalist.org.au%2Farchives – registration and login required.
Replies to this message will be directed back to the list. To create a new message send an email to acipclist@acipc.org.au
To send a message to the list administrator send an email to admin@acipc.org.au
You can unsubscribe manually from this list by sending ‘signoff acipclist’ (without the quotes) to listserv@aicalist.org.au
______________________________________________________________________
This email and any attachments to it (the “Email”) is confidential and is for the use only of the intended recipient, and may not be duplicated or used by any other party without the express consent of the sender. If you are not the intended recipient of the Email, please notify the sender immediately by return email, delete the Email, and do not copy, print, retransmit, store or act in reliance on the Email. St Vincent’s Health Australia (“SVHA”) does not guarantee that the Email is free from errors, viruses or interference. Emails to and from SVHA or its related entities may be scanned and filtered in locations outside Australia.______________________________________________________________________
This email and any attachments to it (the “Email”) is confidential and is for the use only of the intended recipient, and may not be duplicated or used by any other party without the express consent of the sender. If you are not the intended recipient of the Email, please notify the sender immediately by return email, delete the Email, and do not copy, print, retransmit, store or act in reliance on the Email. St Vincent’s Health Australia (“SVHA”) does not guarantee that the Email is free from errors, viruses or interference. Emails to and from SVHA or its related entities may be scanned and filtered in locations outside Australia.MESSAGES POSTED TO THIS LIST ARE SOLELY THE OPINION OF THE AUTHOR, AND DO NOT REPRESENT THE OPINION OF ACIPC.
The use of trade/product/commercial brand names through the list is discouraged by ACIPC. If you wish to discuss specific reference to products or services by brand or commercial names, please do this outside the list.
Archive of all messages are available at http://aicalist.org.au/archives – registration and login required.
Replies to this message will be directed back to the list. To create a new message send an email to acipclist@acipc.org.au
To send a message to the list administrator send an email to admin@acipc.org.au
You can unsubscribe manually from this list by sending ‘signoff acipclist’ (without the quotes) to listserv@aicalist.org.au
- The forum ‘Infexion Connexion’ is closed to new topics and replies.